Eledon Pharmaceuticals, Inc. — Director's Dealing 2017

May 12, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Novus Therapeutics, Inc. (NVUS)
CIK: 0001404281
Period of Report: 2017-05-10

Reporting Person: Katkin Keith (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	12119	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$19.76	2025-12-29	Common Stock (5363)		Direct

Footnotes

F1: All numbers give effect to the 1:9 reverse stock split effected by the Company on May 11, 2017.

F2: This option represents a right to purchase a total of 5,363 shares of the Issuer's Common Stock one quarter of which became fully vested and exercisable on December 30, 2016, with the remaining 4,022.25 shares vesting in equal quarterly installments over the following three years.